Combination Of Isoniazid, HAART More Effective At Preventing TB In HIV-Positive Patients Than Monotherapy, Study Says

Main Category: Tuberculosis
Also Included In: HIV / AIDS
Article Date: 18 Aug 2006 - 8:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:1 star

1 (1 votes)

Healthcare Prof:1 star

1 (1 votes)


A combination of the antibiotic isoniazid and highly active antiretroviral therapy is more effective at preventing active tuberculosis among HIV-positive people than the two treatments on their own, according to a study presented Monday at the XVI International AIDS Conference, Health-e News reports. Richard Chaisson, a professor of infectious diseases at Johns Hopkins University, and colleagues examined the medical records of more than 11,000 HIV-positive adults in Rio de Janeiro, Brazil. The researchers found that the risk of developing TB was reduced by 67% among HIV-positive people who took both isoniazid and HAART, while isoniazid on its own reduced the risk of the disease by 32%, and HAART alone reduced the risk of TB by 51%. The researchers also found that the combination is more beneficial among HIV-positive people with lower CD4+T cell counts. The combination reduced the risk of TB by 66% among HIV-positive people with T cell counts below 350, compared with a 56% risk reduction among HIV-positive people with higher T cell counts, according to the study. Chaisson said although the World Health Organization recommends isoniazid to prevent TB among HIV-positive people and the drug costs less than $1 for a full course of treatment, few physicians prescribe it. The researchers say they plan to continue monitoring the effectiveness of the drugs -- both as a combination therapy and as monotherapies -- at preventing the risk of TB among HIV-positive people in Rio de Janeiro. The research is part of three studies by the Bill & Melinda Gates Foundation-funded Consortium To Respond Effectively to the AIDS/TB Epidemic, which aims to develop new ways to detect and treat TB among HIV-positive people (Thom, Health-e News, 8/13).

Kaisernetwork.org is serving as the official webcaster of the conference. View the guide to coverage and all webcasts, interviews and a daily video round up of conference highlights at http://www.kaisernetwork.org/aids2006.

"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Article adapted by Medical News Today from original press release.
Visit our tuberculosis section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Barbara Martin. "Combination Of Isoniazid, HAART More Effective At Preventing TB In HIV-Positive Patients Than Monotherapy, Study Says." Medical News Today. MediLexicon, Intl., 18 Aug. 2006. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/49848.php>

APA
Barbara Martin. (2006, August 18). "Combination Of Isoniazid, HAART More Effective At Preventing TB In HIV-Positive Patients Than Monotherapy, Study Says." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/49848.php.

Please note: If no author information is provided, the source is cited instead.


Tuberculosis

Most Popular Articles



Follow Our Tuberculosis News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Tuberculosis Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »